ALDX

0.840016.39%
DM

Darlene M. Deptula-Hicks

Independent Director

Ms. Darlene M. Deptula-Hicks, MBA, serves as Chief Financial Officer at Levicept Ltd. since July 2026. She is Independent Director of Aldeyra Therapeutics, Inc. from June 9, 2026. Ms. Deptula-Hicks serves as an Additional Director at Lytix Biopharma AS since January 26, 2026. She served as the Interim Chief Financial Officer of Normunity Inc. since 2024 until 2026 and serves as its Chief Financial Officer since 2026. Ms. Deptula-Hicks has served in an advising role at Normunity since 2023. Ms. Deptula-Hicks was Chief Financial Officer of Grey Wolf Therapeutics since November 2024. Ms. Deptula-Hicks was Independent Non-Executive Director of Avacta Group Plc since June 26, 2024 until 2025. She was Director at Abcuro, Inc. from October 2021 to 2025. She serves as Chief Financial Officer and Director at Aerami Therapeutics Holdings, Inc. from November 2021. She had been the Chief Financial Officer of F-star Therapeutics, Inc since May 2019 and had been its Treasurer since November 20, 2020 and served as its Secretary. She served as Chief Financial Officer at f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. since June 2019. Since January 2018, Ms. Deptula-Hicks has operated Crimson Advisors, a strategic and financial consulting services company and had served as Acting Chief Financial Officer for Northern Biologics, Inc. Ms. Deptula-Hicks served as the Chief Financial Officer and Senior Vice President at T2 Biosystems, Inc. from May 1, 2017 to January 30, 2018. Ms. Deptula-Hicks is an accomplished financial executive in the life sciences and medical technology industries and has experience leading financial operations for both public and private companies. Ms. Deptula-Hicks served as the Chief Financial Officer and Senior Vice President of Pieris Pharmaceuticals, Inc. from September 1, 2015 to February 1, 2017. She served as Secretary and Treasurer of Pieris Pharmaceuticals, Inc. from December 17, 2014 to September 2015. She served as an Acting Chief Financial Officer of Pieris Pharmaceuticals, Inc. from December 17, 2014 to September 2015. Ms. Deptula-Hicks was a Financial Consultant to Pieris AG since November 19, 2014 and provided financial services relating to the Acquisition pursuant to a consulting agreement with the financial advisory firm of Danforth Advisors, LLC or Danforth. She served as an Acting Chief Financial Officer and Treasurer of Pieris and provided services through Danforth. Since June 2012, Ms. Deptula-Hicks served as an Executive Vice President and Chief Financial Officer of Microline Surgical, Inc. From September 11, 2006 to April 2011, Ms. Deptula-Hicks served as an Executive Vice President of Finance and Chief Financial Officer of iCAD, Inc. where she served as its Principal Accounting Officer and Secretary until April 2011 and Treasurer from September 2006 to April 2011. From 2002 to 2006 Ms. Deptula-Hicks served as an Executive Vice President and Chief Financial Officer of ONI Medical Systems, Inc., a venture capital-backed designer and manufacturer of high-field diagnostic imaging systems for orthopedic applications and served as its Vice President. From 1998 to 2001, Ms. Deptula-Hicks served as an Executive Vice President and Chief Financial Officer of Implant Sciences Corporation, an early stage medical device company that had its initial public offering in June of 1999. She served as Vice President and Treasurer of Secure Point Technologies, Inc. (formerly, Implant Sciences Corp.). Prior to 1998, Ms. Deptula-Hicks held various senior financial and accounting positions at Abiomed, Inc., GCA Corporation, Edwards High Vacuum International and Puritan Bennett Corporation. She served as Director of Pieris Pharmaceuticals, Inc. since December 17, 2014. Ms. Deptula-Hicks served as a Director of Giner Life Sciences. Ms. Deptula-Hicks served as a Non-Executive Director of Xenetic Biosciences, Inc. since April 2014 until August 15, 2017 and also its Non-Executive Director since 2006. She served as a Director of US falcon, Inc. She served as an Independent Director of Technest Holdings, Inc. from March 15, 2006 to August 9, 2007 and IMCOR Pharmaceutical Co. since July 22, 2004. She completed an executive education program at Dartmouth College’s Tuck School of Business. She currently serves on the Board of Directors of Abcuro, Inc. and previously served on the Board of Directors of Xentic Biosciences. Ms. Deptula-Hicks received her B.S. in Accounting from Southern New Hampshire University and MBA from Rivier University.

Positions